2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Jeffrey S. Weber, MD, PhD, deputy director and codirector of the Melanoma Research Program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, to discuss some of the main highlights from the 2021 ASCO Annual Meeting in melanoma, including key findings from the phase 3 RELATIVITY-047 trial (NCT03470922), the phase 3 CheckMate-067 trial (NCT01844505), and the phase 3 EORTC 1325/KEYNOTE-054 trial (NCT02362594), among others.
In our exclusive interview, Weber discussed exciting research in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.